Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials

• Anke Harenberg ,

  * E-mail: anke.pagnon@sanofipasteur.com

  Affiliation R&NCS Department, Sanofi Pasteur, Marcy l’Etoile, France

  ⨯
• Aymeric de Montfort,

  Affiliation R&NCS Department, Sanofi Pasteur, Marcy l’Etoile, France

  ⨯
• Frédérique Jantet-Blaudez,

  Affiliation R&NCS Department, Sanofi Pasteur, Marcy l’Etoile, France

  ⨯
• Matthew Bonaparte,

  Affiliation Global Clinical Immunology Department, Sanofi Pasteur, Swiftwater, Pennsylvania, United States of America

  ⨯
• Florence Boudet,

  Affiliation R&NCS Department, Sanofi Pasteur, Marcy l’Etoile, France

  ⨯
• Melanie Saville,

  Affiliation Global Clinical Development, Sanofi Pasteur, Marcy l’Etoile, Lyon, France

  ⨯
• Nicholas Jackson,

  Affiliation Research and Development, Sanofi Pasteur, Lyon, France

  ⨯
• Bruno Guy

  Affiliation Research and Development, Sanofi Pasteur, Lyon, France

  ⨯